Browsing by Author Martyn, Julie

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 8 of 8
Issue DateTitleAuthor(s)Citation
2014Development of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit with Chemotherapy for Symptomatic Ovarian CancerButow, Phyllis; Friedlander, Michael; Gillies, Kim Michelle; King, Madeleine; Martyn, Julie; Mercieca-Bebber, Rebecca; O'Connell, Rachel; Sjoquist, Katrin; Stockler, Martin; Voysey, Merryn; Donovan, Heidi; Oza, Amit; Psychology; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Psychology; School of Public Health: NH&MRC Clinical Trials Centre; Psychology; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreDevelopment of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit with Chemotherapy for Symptomatic Ovarian Cancer, International Journal of Gynecological Cancer, vol.24, 5, 2014,pp 865-873
2013Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG studyBrand, Alison; Donohue, Mark; Gainford, Corona; Gebski, Val; Martyn, Julie; Stockler, Martin; Blinman, Prunella L; Bloomfield, Penny; Friedlander, Michael L.; Grant, Peter Thomas; Kichenadasse, G; Shannon, Catherine; Vaughan, Michelle; Western Clinical School: Medicine (Westmead); Linguistics; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreFeasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study, Journal of Gynecologic Oncology, vol.24, 4, 2013,pp 359-366
2013Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecological Cancer Intergroup Symptom Benefit StudyButow, Phyllis; Friedlander, Michael; Gillies, Kim Michelle; King, Madeleine; Martyn, Julie; O'Connell, Rachel; Sjoquist, Katrin; Stockler, Martin; Voysey, Merryn; Oza, Amit; Psychology; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Psychology; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreHope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecological Cancer Intergroup Symptom Benefit Study, The Oncologist, vol.18, 11, 2013,pp 1221-1228
2017Paragon (ANZGOG-0903): Phase 2 study of anastrozole in women with estrogen or progesterone receptorypositive platinum-resistant or -refractory recurrent ovarian cancerBeale, Philip; deFazio, Anna; Friedlander, Michael; Mapagu, Cristina; Martyn, Julie; Mileshkin, Linda; O'Connell, Rachel; Sjoquist, Katrin; Bonaventura, Anthony; Goh, J; Grant, Peter; Hadley, Alison; McNally, Orla; Scurry, James P; Central Clinical School: Medicine; Western Clinical School: Westmead Institute for Medical Res; NH&MRC Clinical Trials Centre; Childrens Hospital Westmead: Paediatrics & Child Health; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreParagon (ANZGOG-0903): Phase 2 study of anastrozole in women with estrogen or progesterone receptorypositive platinum-resistant or -refractory recurrent ovarian cancer, International Journal of Gynecological Cancer, vol.27, 5, 2017,pp 900-906
2016PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancerLindemann, Kristina; Martyn, Julie; Willson, Melina; Mileshkin, Linda; Roncolato, Felicia; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentrePI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer, Cochrane Database of Systematic Reviews, vol.2016, 4, 2016,pp N/A-N/A
2011The role of hormonal therapy in gynecological cancers-current status and future directionsMartyn, Julie; Sjoquist, Katrin; Edmondson, Richard; Friedlander, Michael; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreThe role of hormonal therapy in gynecological cancers-current status and future directions, International Journal Of Gynecological Cancer, vol.21, 7, 2011,pp 1328-1333
2014Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit studyButow, Phyllis; Friedlander, Michael; Gillies, Kim Michelle; King, Madeleine; Martyn, Julie; O'Connell, Rachel; Sjoquist, Katrin; Stockler, Martin; Voysey, Merryn; Donovan, Heidi; Oza, Amit; Symptom Benefit Study Group, .; Psychology; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Psychology; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreSymptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study, International Journal of Gynecological Cancer, vol.24, 5, 2014,pp 857-864
2009Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer.Butow, Phyllis; Gainford, Corona; King, Madeleine; Martyn, Julie; Stockler, Martin; Donovan, Heidi; Friedlander, Michael; Miller, Brigitte; Oza, Amit; Psychology; School of Public Health: NH&MRC Clinical Trials Centre; Psychology; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreSymptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer., International Journal Of Gynecological Cancer, vol.19, Suppl 2,pp S44-S48